Construct validity, reliability, and threshold value for treatment goals of the Thai version of the 12-item Psoriatic Arthritis Impact of Disease Questionnaire for patients with psoriatic arthritis

dc.contributor.authorChiowchanwisawakit P.
dc.contributor.authorOrawongpaisarn A.
dc.contributor.authorKatchamart W.
dc.contributor.correspondenceChiowchanwisawakit P.
dc.contributor.otherMahidol University
dc.date.accessioned2024-04-21T18:09:05Z
dc.date.available2024-04-21T18:09:05Z
dc.date.issued2024-04-01
dc.description.abstractObjective: To determine the construct validity, reliability, and treatment goal threshold of a Thai-language version of the 12-item Psoriatic Arthritis Impact of Disease (Thai-PsAID) questionnaire in patients with psoriatic arthritis (PsA). Methods: This cross-sectional study involved administering the proposed Thai-PsAID to 117 Thai patients with PsA. Reliability was assessed by Cronbach's α test and intraclass correlation coefficient (ICC). Construct validity was assessed using Spearman correlation with clinical disease activity index for psoriatic arthritis (cDAPSA), the Health Assessment Questionnaire (HAQ), EQ-5D index, and the patient-acceptable symptom state (PASS). The optimal cutoff score of the Thai-PsAID for minimal disease activity (MDA) was determined by receiver operating characteristic curves. Results: Participants had a mean age of 49.5 years, 61 (52.1%) were female, and the median disease duration was 5 years. The median Thai-PsAID score was 2.1, with a Cronbach's α coefficient of.95 and an ICC of 0.77. The mean time to complete the Thai-PsAID was 2.1 min, with no missing data. The Thai-PsAID score demonstrated a moderate correlation with the cDAPSA, HAQ, and EQ-5D with indices (Spearman's rho of.64,.54, and −.55, respectively). The cutoff of 2.7 has 81%–84% sensitivity and 69%–85% specificity for classifying patients with MDA, satisfied PASS, and indicating no need to escalate medication. Conclusions: The Thai-PsAID is a valid, reliable, and feasible tool for measuring PsA prognosis. A cutoff of 2.7 accurately discriminates MDA and PASS and indicates no need for medication escalation. The Thai-PsAID may be used as a standalone measure.
dc.identifier.citationInternational Journal of Rheumatic Diseases Vol.27 No.4 (2024)
dc.identifier.doi10.1111/1756-185X.15139
dc.identifier.eissn1756185X
dc.identifier.issn17561841
dc.identifier.scopus2-s2.0-85190264494
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/98041
dc.rights.holderSCOPUS
dc.subjectMedicine
dc.titleConstruct validity, reliability, and threshold value for treatment goals of the Thai version of the 12-item Psoriatic Arthritis Impact of Disease Questionnaire for patients with psoriatic arthritis
dc.typeArticle
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85190264494&origin=inward
oaire.citation.issue4
oaire.citation.titleInternational Journal of Rheumatic Diseases
oaire.citation.volume27
oairecerif.author.affiliationSiriraj Hospital

Files

Collections